Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update

@article{Sriretnakumar2015PharmacogeneticsOC,
  title={Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update},
  author={Venuja Sriretnakumar and Eric Huang and Daniel J. M{\"u}ller},
  journal={Expert Opinion on Drug Metabolism \& Toxicology},
  year={2015},
  volume={11},
  pages={1709 - 1731}
}
Introduction: Clozapine (CLZ) is the most effective treatment for treatment-resistant schizophrenia (SCZ) patients, with potential added benefits of reduction in suicide risk and aggression. However, CLZ is also mainly underused due to its high risk for the potentially lethal side-effect of agranulocytosis as well as weight gain and related metabolic dysregulation. Pharmacogenetics promises to enable the prediction of patient treatment response and risk of adverse effects based on patients… 
Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications
TLDR
Overall, several gene variants related to antipsychotic response and adverse effects in the treatment of patients with schizophrenia have been reported, and several commercial pharmacogenomic tests have become available, however, further well-designed investigations and replication studies in large and well-characterized samples are needed to facilitate the application of PGx findings to clinical practice.
New findings in pharmacogenetics of schizophrenia
TLDR
The findings to date are promising and provide a better understanding of the development of side effects and response to antipsychotics, however, more comprehensive investigations in large, well characterized samples will bring us closer to clinically actionable findings.
Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics
TLDR
Clinical pharmacogenomic testing – to personalize clozapine treatment and identify patients at high risk of treatment failure or of adverse events – has moved closer over the last 20 years, however, to develop such testing that could be used clinically will require larger, multicenter, prospective studies.
Clozapine as a Model for Antipsychotic Development
TLDR
This review discusses the history of clozapine, landmark studies, and its clinical advantages and disadvantages, and highlights some of the advances from pharmacogenetic studies on clozAPine and focuses on studies of clazapine using unbiased approaches such as pharmacogenomics and gene expression profiling.
Clozapine’s critical role in treatment resistant schizophrenia: ensuring both safety and use
TLDR
Clozapine remains the only treatment indicated in TRS, but it is dramatically underutilized and efforts must be implemented that ensure its use in this population while maximizing safety.
Naringin treatment improved main clozapine‐induced adverse effects in rats; emphasis on weight gain, metabolic abnormalities, and agranulocytosis
TLDR
Findings may suggest that naringin possesses a potential add‐on benefit to clozapine in treatment of schizophrenia, which has been recently reserved for resistant schizophrenia.
Clozapine pharmacogenomics: a review of efficacy, pharmacokinetics, and agranulocytosis
TLDR
Current landscape of pharmacogenomic research in CLZ continues to be limited by small sample sizes and low power, however, many promising candidate genes have been discovered and should be further investigated with larger cohorts.
...
...

References

SHOWING 1-10 OF 118 REFERENCES
The pharmacogenetics of antipsychotic-induced adverse events
TLDR
Overall, genetic studies have been successful in identifying strong findings, in particular for antipsychotic-induced weight gain and to some extent for tardive dyskinesia, and the next challenge will be to create predictive algorithms that can be used for clinical practice.
Pharmacogenetics and outcome with antipsychotic drugs
TLDR
The most promising genetic markers of antipsychotic treatment outcomes are discussed, and current translational research efforts that aim to bring these pharmacogenetic findings to the clinic in the near future are presented.
Association between CYP1A2 gene single nucleotide polymorphisms and clinical responses to clozapine in patients with treatment-resistant schizophrenia
TLDR
Routine screening for CYP1A2 gene SNPs prior to start clozapine is currently unwarranted, and future longitudinal genome-wide association studies investigating clinical and pharmacogenetic variables together are suggested.
D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.
TLDR
The authors conducted the first meta-analysis to examine the relationship between DRD2 polymorphisms and antipsychotic drug response in schizophrenia patients, finding that variation in the DRD(2) gene is associated with clinical response to antipsychotics.
Clozapine: A Clinical Review of Adverse Effects and Management
TLDR
The history, pharmacology, management of side effects, and fetal and neonatal effects of clozapine are covered, which have resulted in the expansion of its use from refractory schizophrenia to schizoaffective disorders, affective disorders, some neurological disorders, aggression, as well as psychosis in patients with dementia and parkinsonism.
Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia
TLDR
It is demonstrated that the results of pharmacogenetic studies in schizophrenia depend heavily on their outcome definitions and that combined clinical and pharmacogenetics models have better predictive values.
Association Study of 27 Annotated Genes for Clozapine Pharmacogenetics: Validation of Preexisting Studies and Identification of a New Candidate Gene, ABCB1, for Treatment Response
TLDR
A new candidate gene, ABCB1, is found for treatment response, which may provide a hypothesis on the relationship between the blood-brain distribution of CLZ and its clinical efficacy, and is validated through an integrative study.
Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain.
TLDR
These data implicate MC4R in extreme SGA-induced weight gain and related metabolic disturbances, and could lead to alternative treatment strategies in this population of patients undergoing first exposure to antipsychotic drugs.
Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.
TLDR
The increasing risk of agranulocytosis with age and the reduced incidence after the first six months of treatment provide additional guidelines for the prescription and monitoring of clozapine treatment in the future.
...
...